Under New CEO, GSK Will Leverage OTCs In Emerging Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
Glaxo will look at opportunities to expand its nonprescription business, as OTC and other products have more long-term sales consistency than Rx drugs, North American Pharmaceuticals President Viehbacher says.
You may also be interested in...
GSK Acts On Cost Plan, Cuts Research Jobs
U.K. firm’s busy spring includes internal downsizing, external investments.
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.